Neurolixis Appoints Mark H.N. Corrigan, M.D. to Advisory Board

Spread the Word
Listed Under

* Rett
* Parkinson S Disease
* Neurolixis

* Biotech

* Dana Point - California - US

* Executives

DANA POINT, Calif. - May 29, 2015 - PRLog -- Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Mark Corrigan, M.D. to its Advisory Board. Dr. Corrigan is a seasoned life sciences executive with broad healthcare industry experience including CNS drug development.

Dr. Corrigan is Chairman of the Board of Epirus Biopharmaceuticals, Inc. a public biopharmaceutical company, and from 2010 to 2014, he previously served as a director, president and chief executive officer of Zalicus Inc. prior to its merger with Epirus Biopharmaceuticals in July 2014. Prior to Zalicus, Dr. Corrigan joined the specialty pharmaceutical company Sepracor Inc. in 2003 (now known as Sunovion Pharmaceuticals, Inc.) where he served as Executive Vice President of Research and Development until December 2009. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina, School of Medicine, focusing on psychoneuroendocrinology; he maintains a faculty appointment as Adjunct Professor in the Psychiatry Dept. He is a Distinguished Fellow of the American Psychiatric Association. Dr. Corrigan has also chaired the Scientific Committee of the boards of directors of Avanir Pharmaceuticals and of Cubist Pharmaceuticals, Inc. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.

"It is a pleasure to welcome Mark to the Neurolixis Advisory Board," commented Mark Varney, Ph.D., CEO, "Mark brings many years of experience and a deep knowledge of CNS research and development. We look forward to the insights he will provide to facilitate the advancement of our programs at Neurolixis."

About Neurolixis, Inc.

Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing small molecule drugs for the treatment of neurological disorders such as Parkinson’s disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at

Forward Looking Statement Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release.

Mark Varney
Email:*** Email Verified
Tags:Rett, Parkinson S Disease, Neurolixis
Location:Dana Point - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Neurolixis, Inc. News
Most Viewed
Daily News

Like PRLog?
Click to Share